Patent ID: 11958893
Assignee: CUE BIOPHARMA, INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C | IPC A  C

Claim 12:
13. A method of treating cancer according to claim 1, wherein:
a) the first polypeptide of each heterodimer comprises, in order from N-terminus to C-terminus:
i) the peptide epitope, wherein the peptide epitope has a length of 8-12 amino acids;
ii) the peptide linker; and
iii) the β2M polypeptide, wherein the β2M polypeptide comprises an amino acid sequence having at least 95% amino acid sequence identity to 21-119 of any one of the amino acid sequences set forth in SEQ ID NOs:95-98;
b) the second polypeptide of each heterodimer comprises, in order from N-terminus to C-terminus:
i) the first variant IL-2 polypeptide;
ii) the second variant IL-2 polypeptide;
iii) the MHC class I heavy chain polypeptide, wherein the MHC class I heavy chain polypeptide comprises an amino acid sequence having at least 95% amino acid sequence identity to the amino acid sequence set forth in SEQ ID NO:50; and
iv) the Ig Fc polypeptide, and wherein the second polypeptide comprises an independently selected peptide linker between one or more of:
a) the first variant IL-2 polypeptide and the second variant IL-2 polypeptide;
b) the second variant IL-2 polypeptide and the MHC class I heavy chain polypeptide; and
c) the MHC class I heavy chain polypeptide and the Ig Fc polypeptide.